The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing ...

Findings showed secukinumab demonstrated statistically significant and clinically meaningful sustained remission at week 52 vs placebo. Topline data were announced from a phase 3 trial evaluating ...

All About Polymyalgia Rheumatica and Temporal Arteritis: From Symptoms to Treatments: By Shreoshree Chakrabarty Polymyalgia rheumatica (PMR) and temporal arteritis, also known as giant cell arteritis ...

For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the interleukin-6 receptor α, is ...

(RTTNews) - Novartis (NVS,NOVN.SW) announced that its interleukin-17A inhibitor Cosentyx (secukinumab) met the primary and all secondary endpoints in the Phase III REPLENISH trial. The study evaluated ...

Novartis said that its immunology drug Cosentyx met the primary target and all secondary ones in a late-stage trial for the treatment of patients with inflammatory disease polymyalgia rheumatica.